Key issues in inhibitor management in patients with haemophilia

Affiliations

¹ Katherine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, United Kingdom.
² Department for Internal Medicine, Haemophilia Treatment Centre Vivantes, Klinikum im Friedrichshain, Berlin, Germany.
³ Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
⁴ "Angelo Bianchi Bonomi" Haemophilia and Thrombosis Centre, IRCCS Ca' Granda, Ospedale Maggiore Policlinico Foundation, Milan, Italy.
⁵ Haematology Department, Regional University Hospital "Carlos Haya", Málaga, Spain.
⁶ IHTC Haemophilia Unit "Cláudio Luis Pizzigatti Corrêa", INCTS Blood Centre UNICAMP, University of Campinas, São Paulo, Brazil.

Review

Keith Gomez et al. Blood Transfus. 2014 Jan.

. 2014 Jan;12 Suppl 1(Suppl 1):s319-29.

doi: 10.2450/2013.0246-12. Epub 2013 Dec 3.

¹ Katherine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, United Kingdom.
² Department for Internal Medicine, Haemophilia Treatment Centre Vivantes, Klinikum im Friedrichshain, Berlin, Germany.
³ Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
⁴ "Angelo Bianchi Bonomi" Haemophilia and Thrombosis Centre, IRCCS Ca' Granda, Ospedale Maggiore Policlinico Foundation, Milan, Italy.
⁵ Haematology Department, Regional University Hospital "Carlos Haya", Málaga, Spain.
⁶ IHTC Haemophilia Unit "Cláudio Luis Pizzigatti Corrêa", INCTS Blood Centre UNICAMP, University of Campinas, São Paulo, Brazil.

No abstract available

References

1. Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. 1994;83:2428–35. - PubMed
1. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med. 1993;328:453–9. - PubMed
1. Hay CR, Baglin TP, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO) Br J Haematol. 2000;111:78–90. - PubMed
1. Lawrence JS, Johnson JB. The presence of a circulating anticoagulant in a male member of a hemophiliac family. Trans Am Clin Climatol Assoc. 1941;57:223–31. - PMC - PubMed
1. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5:1904–13. - PubMed